JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $438
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Vertex Pharmaceuticals (VRTX) and raises the price target from $390 to $438.
February 01, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Vertex Pharmaceuticals and raises the price target from $390 to $438.
The increase in price target by a reputable analyst like Jessica Fye from JP Morgan is a strong bullish signal for Vertex Pharmaceuticals. It suggests a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100